CN110841027A - Pharmaceutical composition for treating gastrointestinal diseases and application thereof - Google Patents
Pharmaceutical composition for treating gastrointestinal diseases and application thereof Download PDFInfo
- Publication number
- CN110841027A CN110841027A CN201911286787.1A CN201911286787A CN110841027A CN 110841027 A CN110841027 A CN 110841027A CN 201911286787 A CN201911286787 A CN 201911286787A CN 110841027 A CN110841027 A CN 110841027A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- pharmaceutical composition
- gastrointestinal diseases
- treating gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating gastrointestinal diseases, which comprises the following components in parts by weight: 10-30 parts of litsea cubeba oil, 20-40 parts of cloud sesame oil, 10-30 parts of linseed oil, 10-30 parts of sea buckthorn oil, 10-30 parts of amomum villosum, 5-15 parts of wolfberry seed oil and 5-15 parts of ganoderma spore oil. The medicinal composition prepared from the litsea cubeba oil, the linseed oil, the cloud sesame oil, the sea buckthorn oil, the amomum villosum, the medlar seed oil and the ganoderma lucidum spore oil according to a certain proportion has the effect of treating gastrointestinal diseases.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating gastrointestinal diseases and application thereof.
Background
Gastroenteropathy is a common frequently-occurring disease, and the total incidence rate accounts for about 20 percent of the population. The incidence rate is higher with the older people, especially the middle-aged and the elderly people over 50 years old are more common, and men are higher than women, if the treatment is not performed in time, the diseases are repeatedly attacked for a long time, and the diseases are easily transformed into cancer. Gastrointestinal diseases are always regarded as difficult and complicated by doctors, and once the gastrointestinal diseases are treated, the gastrointestinal diseases can be controlled or cured by timely treatment and long-term administration. Wherein, acute and chronic gastroenteritis are common diseases and frequently encountered diseases, and are clinically manifested by abdominal discomfort, abdominal pain, nausea, vomiting, abdominal distension, diarrhea, eructation, acid regurgitation and inappetence.
The western medicine treatment for the gastrointestinal diseases mainly aims at relieving symptoms, does not improve atrophic gastric mucosa and intestinal mucosa, and only treats the symptoms, but not the root causes. Secondly, the adverse effect is large, and the headache and nausea of the patient are easily caused, so that the digestive system and the blood system of the body are abnormal, and the Chinese patent medicines which are clinically used for treating the intestines and the stomach have a plurality of varieties, such as: the Sanjiuweitai granules, the Wenweishu granules, the Yangweishu granules, the Yanyanning tablets, the Changweining tablets and the like have certain curative effect on the intestinal tract diseases, but have slow effect and the defect of incapability of treating both symptoms and root causes.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for treating gastrointestinal diseases and application thereof, so as to solve the technical problems.
In order to achieve the purpose, the technical scheme of the invention is as follows:
in a first aspect, the present invention provides a pharmaceutical composition for treating gastrointestinal diseases, comprising, by weight: 10-30 parts of litsea cubeba oil, 20-40 parts of cloud sesame oil, 10-30 parts of linseed oil, 10-30 parts of sea buckthorn oil, 10-30 parts of amomum villosum, 5-15 parts of wolfberry seed oil and 5-15 parts of ganoderma spore oil.
Preferably, the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 17-22 parts of litsea cubeba oil, 18-22 parts of linseed oil, 20-25 parts of cloud sesame oil, 17-23 parts of sea buckthorn oil, 17-23 parts of amomum villosum, 9-11 parts of wolfberry seed oil and 9-11 parts of ganoderma spore oil.
Further preferably, the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 20 parts of litsea cubeba oil, 20 parts of linseed oil, 23 parts of cloud sesame oil, 20 parts of sea buckthorn oil, 20 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma spore oil.
Further preferably, the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 17 parts of litsea cubeba oil, 18 parts of linseed oil, 25 parts of cloud sesame oil, 17 parts of sea buckthorn oil, 17 parts of amomum villosum, 9 parts of medlar seed oil and 9 parts of ganoderma spore oil.
Further preferably, the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 22 parts of litsea cubeba oil, 22 parts of linseed oil, 20 parts of cloud sesame oil, 23 parts of sea buckthorn oil, 23 parts of amomum villosum, 11 parts of medlar seed oil and 11 parts of ganoderma spore oil.
Further preferably, the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 18 parts of litsea cubeba oil, 20 parts of linseed oil, 23 parts of cloud sesame oil, 21 parts of sea buckthorn oil, 21 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma spore oil.
In a second aspect, the present invention provides a use of the pharmaceutical composition for treating gastrointestinal diseases according to the first aspect in the preparation of a medicament for treating intestinal diseases.
In a third aspect, the present invention provides the use of a pharmaceutical composition for the treatment of gastrointestinal disorders as described in the first aspect, in the manufacture of a medicament for the treatment of gastric disorders.
Pharmacological analysis:
litsea cubeba oil: the natural essential oil extracted from the fresh litsea cubeba is yellowish, contains a large amount of citral, and the litsea cubeba has the functions of warming spleen and stomach, dispelling cold and relieving pain, so that the natural essential oil is suitable for stomach cold pain and symptoms such as hiccup, vomiting, abdominal distension and the like caused by stomach cold, and is often used together with galangal and the like;
sesame oil: the essential oil is extracted from the Yunnan hemp seed, contains a large amount of grease (such as lecithin and the like), protein, unsaturated fatty acid (such as omega-6 (linoleic acid) and omega-3 (linoleic acid)) and various mineral trace elements, and has the effects of assisting in conditioning the blood fat level, preventing and treating heart diseases, relaxing bowel, resisting cancer and the like;
ganoderma lucidum spore oil: is yellow transparent liquid, is rich in various saturated fatty acids, unsaturated fatty acids, ganoderic acid and other active ingredients, and is suitable for severe adverse reactions such as inappetence, emesis, weight loss, leucopenia, anemia, anti-infection capability reduction and the like and damage to liver, kidney and heart functions;
the medlar seed oil is rich in linoleic acid, gamma-linolenic acid, VE, β -carotene, alkaloid, medlar polysaccharide and other active ingredients, the linoleic acid, the gamma-linolenic acid, the VE, β -carotene and the alkaloid promote blood circulation, can directly participate in metabolism, improve the functions of the hypothalamus and pituitary gonads of a human body, and has a main regulating effect on maintaining normal physiology;
linseed oil: the linseed powder is prepared from linseed, and is greatly helpful for preventing organ and tissue inflammation, wherein meningitis, tendinitis, tonsillitis, gastritis, ileitis, colitis, arteritis, phlebitis, prostate inflammation, nephritis, splenitis, hepatitis, pancreatitis, otitis and the like, as well as tinea and sore, so that the linseed powder improves the functions of intestines, increases the absorption capacity, increases the peristalsis capacity of the intestines to ensure normal defecation, and reduces constipation;
sea buckthorn oil: the sea buckthorn oil is precious natural oil extracted from fruits of natural plant sea buckthorn, has the effects of nourishing yin, promoting the secretion of saliva, diminishing inflammation, protecting membranes, clearing heat and relieving pain, is suitable for yin deficiency type chronic gastritis and is also suitable for various types of chronic gastritis;
amomum villosum lour: contains camphor, borneol and other components, and has light fragrance, and can tranquilize mind, eliminate dampness, promote appetite, warm spleen, check diarrhea, regulate qi, prevent miscarriage, and treat deficiency-cold of spleen and stomach, indigestion, emesis, diarrhea, pernicious vomiting, and threatened abortion.
Compared with the prior art, the invention has the beneficial effects that:
the medicinal composition prepared from the litsea cubeba oil, the linseed oil, the cloud sesame oil, the sea buckthorn oil, the amomum villosum, the medlar seed oil and the ganoderma lucidum spore oil according to a certain proportion has the effect of treating gastrointestinal diseases.
Detailed Description
The following further describes the embodiments of the present invention. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Example 1
The pharmaceutical composition for treating gastrointestinal diseases provided by the embodiment comprises the following components in parts by weight: 20 parts of litsea cubeba oil, 20 parts of linseed oil, 23 parts of cloud sesame oil, 20 parts of sea buckthorn oil, 20 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma spore oil.
Example 2
The pharmaceutical composition for treating gastrointestinal diseases provided by the embodiment comprises the following components in parts by weight: 17 parts of litsea cubeba oil, 18 parts of linseed oil, 25 parts of cloud sesame oil, 17 parts of sea buckthorn oil, 17 parts of amomum villosum, 9 parts of medlar seed oil and 9 parts of ganoderma spore oil.
Example 3
The pharmaceutical composition for treating gastrointestinal diseases provided by the embodiment comprises the following components in parts by weight: 22 parts of litsea cubeba oil, 22 parts of linseed oil, 20 parts of cloud sesame oil, 23 parts of sea buckthorn oil, 23 parts of amomum villosum, 11 parts of medlar seed oil and 11 parts of ganoderma spore oil.
Example 4
The pharmaceutical composition for treating gastrointestinal diseases provided by the embodiment comprises the following components in parts by weight: 18 parts of litsea cubeba oil, 20 parts of linseed oil, 23 parts of cloud sesame oil, 21 parts of sea buckthorn oil, 21 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma spore oil.
Example 5
The pharmaceutical composition for treating gastrointestinal diseases provided by the embodiment comprises the following components in parts by weight: 20 parts of litsea cubeba oil, 28 parts of cloud sesame oil, 20 parts of linseed oil, 22 parts of sea buckthorn oil, 21 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma spore oil.
Example 6
The pharmaceutical composition for treating gastrointestinal diseases provided by the embodiment comprises the following components in parts by weight: 30 parts of litsea cubeba oil, 20 parts of cloud sesame oil, 10 parts of linseed oil, 30 parts of sea buckthorn oil, 30 parts of amomum villosum, 5 parts of medlar seed oil and 5 parts of ganoderma spore oil.
Example 7
The pharmaceutical composition for treating gastrointestinal diseases provided by the embodiment comprises the following components in parts by weight: 20 parts of linseed oil, 40 parts of cloud sesame oil, 20 parts of sea buckthorn oil, 20 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma lucidum spore oil.
Comparative example 1
The medicine composition for treating gastrointestinal diseases comprises the following components in parts by weight: 20 parts of litsea cubeba oil, 20 parts of linseed oil, 20 parts of sea buckthorn oil, 20 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma lucidum spore oil.
Comparative example 2
The medicine composition for treating gastrointestinal diseases comprises the following components in parts by weight: 20 parts of litsea cubeba oil, 20 parts of linseed oil, 23 parts of cloud sesame oil, 20 parts of sea buckthorn oil, 20 parts of amomum villosum and 10 parts of wolfberry seed oil.
Comparative example 3
The medicine composition for treating gastrointestinal diseases comprises the following components in parts by weight: 20 parts of litsea cubeba oil, 20 parts of linseed oil, 23 parts of cloud sesame oil, 20 parts of sea buckthorn oil, 20 parts of amomum villosum and 10 parts of wolfberry seed oil.
Effect example 1 experimental treatment observation of the pharmaceutical composition of the present invention on a mouse model of chronic gastritis
Selecting 120 SD mice with the weight of 200-220 g, wherein the male and female mice are half of each SD mouse and are randomly divided into 12 groups, one group is a normal control group, and the rest groups are molded by the following molding method: the mice are bred adaptively for 3 days, are fed with normal diet and are drunk freely, and the mice are drenched with 60 percent ethanol every 10 days in the first month, wherein the specific dosage is that each mouse is drenched with 2mL of 60 percent ethanol once, and a 20mmol/L sodium deoxycholate solution (prepared by distilled water) is taken as a beverage to be drunk by the mice randomly; and (3) respectively drinking the mice in the second and third months by using 30% ethanol and 10mmol sodium deoxycholate solution, alternately changing every 7 days, successfully molding, feeding the mice under the same condition, and conventionally feeding the mice with standard feed particles, wherein 10 groups of the pharmaceutical compositions in the embodiments 1 to 7 and the comparative examples 1 to 3 are respectively gavaged for 1 time every day according to 2mL dose, one group is a blank control group, the blank control group and the normal control group are respectively gavaged with distilled water with the same volume, the continuous administration is carried out for 10 days, and relevant index detection is carried out after the administration is finished. After the medication was completed, the animals of each group were fasted for 24 hours (free drinking water), sacrificed by cervical dislocation, the whole stomach was taken, the condition of the gastric mucosa was visually observed, surface blood was washed off, the stomach was opened along the greater curvature of the stomach by filter paper, the stomach was rinsed with 5mL of distilled water and rinsed 3 times in the above-mentioned washing solution, the supernatant of the gastric juice specimen was analyzed, the free acid was determined by titration, the pepsin activity was determined by mott's method, and the test results are shown in table 1.
TABLE 1 test results
The test results in table 1 show that the concentration of the titrated gastric juice acid in the colon of the mouse after molding is obviously reduced, the titrated gastric juice acid is recovered to be close to normal after the administration treatment, and the pepsin activity in the gastric juice is also recovered to be close to normal after the pharmaceutical composition of example 1 is taken, which shows that the pharmaceutical composition provided by the invention has the synergistic effect among the components, and the components are reasonably matched according to a certain proportion, so that the pharmaceutical composition has good quality effect on chronic gastritis.
Effect example 2
Selecting 120 SD mice with the weight of 200-220 g, wherein the male and female mice are half of each SD mouse and are randomly divided into 12 groups, one group is a normal control group, and the rest groups are molded by the following molding method: dissolving Dextran Sodium Sulfate (DSS) in a water bottle, freely drinking Balb/c mice for 8 days to induce a test colitis model, wherein SD mice successfully modeled have dull and dull eyes, dark and curled hair and hematochezia, feeding the SD mice under the same condition, conventionally feeding standard feed particles, wherein 10 groups of the SD mice are respectively gavaged with the pharmaceutical compositions of the examples 1-7 and the comparative examples 1-3, each group is gavaged for 1 time every day according to 2mL dose, one group is a blank control group, the blank control group and a normal control group are respectively gavaged with distilled water with the same volume, the pharmaceutical compositions are continuously fed for 14 days, relevant index detection is carried out after the dosing is finished, and the test results are shown in Table 2.
TABLE 2 test results
As can be seen from the test results in table 2, the colon of the mouse is significantly shortened after molding, and the condition is recovered after administration treatment, compared with the pharmaceutical compositions obtained in comparative examples 1 to 3, the pharmaceutical compositions of examples 1 to 7 can significantly increase the colon tissue of the mouse, and the pharmaceutical composition of example 1 has the best effect of treating colitis and the colon tissue length is not much different from the colon tissue length of the normal control group, which indicates that the pharmaceutical composition of example 1 has recovered the colon tissue atrophy caused by colitis to the normal level, which also indicates that the components of the pharmaceutical composition provided by the present invention have a synergistic effect, and the components are reasonably matched according to a certain proportion, so that the intestinal barrier effect can be effectively enhanced, and the pharmaceutical composition has a significant therapeutic effect on colitis.
Clinical tests are carried out on the pharmaceutical composition prepared in example 1, and the total effective rate is 98.7%. The following is further explained by some practical cases:
the patient populus, male, or 49 years old is diagnosed with colon cancer by hospital because the left abdomen is found to have tumor and feels abdominal distension, after the colon is removed by operation, the pharmaceutical composition of example 1 is orally taken twice a day with 2mL each time after 30 days, after the colon is removed, the colon is removed by operation, no abnormal result is found by hospital review, and no relapse is seen after follow-up after one year.
After a patient is diagnosed with chronic gastritis by a hospital, the patient is taken with the pharmaceutical composition prepared in the embodiment 1 of the invention 2 times a day and 2mL of the pharmaceutical composition every 2 days, the dull pain in the gastric cavity of the patient is obviously relieved, the abdominal distension is not done, the diarrhea is not done, the patient can take food, the patient is followed up after half a month, the patient has normal diet, and the patient is effectively treated.
After a patient is applied to a certain patient, male or 46 years old, is diagnosed to have chronic atrophic gastritis, esophageal erosion and gastric angle ulcer (stage H1) in a hospital, the patient is cured after 10 days by taking the pharmaceutical composition prepared in the embodiment 1 of the invention 2 times a day with 2mL each time, and the patient is followed up after half a month, the patient has normal diet, and the patient is effectively treated.
The embodiments of the present invention have been described in detail, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, and the scope of protection is still within the scope of the invention.
Claims (8)
1. The pharmaceutical composition for treating gastrointestinal diseases is characterized by comprising the following components in parts by weight: 10-30 parts of litsea cubeba oil, 20-40 parts of cloud sesame oil, 10-30 parts of linseed oil, 10-30 parts of sea buckthorn oil, 10-30 parts of amomum villosum, 5-15 parts of wolfberry seed oil and 5-15 parts of ganoderma spore oil.
2. The pharmaceutical composition for treating gastrointestinal diseases according to claim 1, wherein the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 17-22 parts of litsea cubeba oil, 20-25 parts of cloud sesame oil, 18-22 parts of linseed oil, 17-23 parts of sea buckthorn oil, 17-23 parts of amomum villosum, 9-11 parts of wolfberry seed oil and 9-11 parts of ganoderma spore oil.
3. The pharmaceutical composition for treating gastrointestinal diseases according to claim 2, wherein the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 20 parts of litsea cubeba oil, 20 parts of linseed oil, 23 parts of cloud sesame oil, 20 parts of sea buckthorn oil, 20 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma spore oil.
4. The pharmaceutical composition for treating gastrointestinal diseases according to claim 2, wherein the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 17 parts of litsea cubeba oil, 18 parts of linseed oil, 25 parts of cloud sesame oil, 17 parts of sea buckthorn oil, 17 parts of amomum villosum, 9 parts of medlar seed oil and 9 parts of ganoderma spore oil.
5. The pharmaceutical composition for treating gastrointestinal diseases according to claim 2, wherein the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 22 parts of litsea cubeba oil, 22 parts of linseed oil, 20 parts of cloud sesame oil, 23 parts of sea buckthorn oil, 23 parts of amomum villosum, 11 parts of medlar seed oil and 11 parts of ganoderma spore oil.
6. The pharmaceutical composition for treating gastrointestinal diseases according to claim 2, wherein the pharmaceutical composition for treating gastrointestinal diseases comprises the following components in parts by weight: 18 parts of litsea cubeba oil, 20 parts of linseed oil, 23 parts of cloud sesame oil, 21 parts of sea buckthorn oil, 21 parts of amomum villosum, 10 parts of medlar seed oil and 10 parts of ganoderma spore oil.
7. Use of the pharmaceutical composition for treating gastrointestinal diseases according to any one of claims 1 to 6 in the preparation of a medicament for treating intestinal diseases.
8. Use of the pharmaceutical composition for treating gastrointestinal diseases according to any one of claims 1 to 6 in the preparation of a medicament for treating gastric diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911286787.1A CN110841027A (en) | 2019-12-14 | 2019-12-14 | Pharmaceutical composition for treating gastrointestinal diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911286787.1A CN110841027A (en) | 2019-12-14 | 2019-12-14 | Pharmaceutical composition for treating gastrointestinal diseases and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110841027A true CN110841027A (en) | 2020-02-28 |
Family
ID=69609721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911286787.1A Pending CN110841027A (en) | 2019-12-14 | 2019-12-14 | Pharmaceutical composition for treating gastrointestinal diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110841027A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913626A (en) * | 2017-03-16 | 2017-07-04 | 杨本雷 | It is a kind of to treat pharmaceutical composition of enterogastritis and preparation method thereof, preparation and application |
-
2019
- 2019-12-14 CN CN201911286787.1A patent/CN110841027A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913626A (en) * | 2017-03-16 | 2017-07-04 | 杨本雷 | It is a kind of to treat pharmaceutical composition of enterogastritis and preparation method thereof, preparation and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100434107C (en) | Acne clearing decoction | |
| CN103784933B (en) | Recurrent oral ulceration falls apart | |
| CN103751739A (en) | Traditional Chinese medicine composition for treating chronic gastritis, application of composition in preparation of medicine for treating chronic gastritis, and preparation method of composition | |
| CN109223637A (en) | Subprostrate sophora herbal mixture toothpaste and preparation method | |
| CN103585521B (en) | A kind of Chinese medicine composition being used for the treatment of dyspepsia, eating accumulation | |
| KR100566542B1 (en) | A health food composition for prevention and treatment of allergic rhinitis and influenza and a method for preparation thereof | |
| CN106913626B (en) | A kind of pharmaceutical composition for treating enterogastritis and preparation method thereof, preparation and application | |
| CN110841027A (en) | Pharmaceutical composition for treating gastrointestinal diseases and application thereof | |
| CN102389562A (en) | Traditional Chinese medicine composition for treating indigestion in children | |
| CN100337681C (en) | Gastric ulcer treating medicine | |
| CN103550744B (en) | A kind of pure Chinese medicinal preparation for oral ulcer | |
| CN102670922B (en) | Traditional Chinese medicine oral fluid with seeds of feather cockscomb for treating diarrhea and preparing method thereof | |
| CN105412572A (en) | Traditional Chinese medicine composition for treating heart and spleen heat accumulation recurrent oral ulceration | |
| CN101897726B (en) | Traditional Chinese medicinal powder for treating oral ulcer | |
| CN110433271A (en) | A kind of pharmaceutical composition and its preparation method and application for treating functional dyspepsia FD | |
| CN101856410B (en) | Hemostatic and antiphlogistic medicament and use thereof | |
| CN102091138A (en) | Gastrointestinal tablet and preparation process thereof | |
| CN102406790A (en) | Traditional Chinese medicine capsule for treating hyperplasia of mammary glands and preparation method thereof | |
| RU2306144C1 (en) | Therapeutical agent, uses thereof and method for diseases treatment and prophylaxis | |
| CN106822855B (en) | Traditional Chinese medicine composition for preventing and treating gastric precancerous lesion and preparation method and application thereof | |
| CN104784537A (en) | Traditional Chinese medicine composition for treating tuberculous pleurisy | |
| CN105169199A (en) | Traditional Chinese medicinal composition for treating functional dyspepsia with syndrome of liver-stomach disharmony | |
| CN104906352A (en) | Traditional Chinese medicine liquid for treating deficiency-fire flaring-up type infantile oral ulcer and preparation method thereof | |
| CN110327432A (en) | A kind of drug and preparation method thereof for treating gastric ulcer and erosive gastritis | |
| CN103211988A (en) | Pharmaceutical composition for treating porcine infectious gastrointestinal inflammations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200228 |